Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?

Antibody-mediated central nervous system (CNS) disorders including those associated with aquaporin-4 or myelin oligodendrocyte glycoprotein IgG and autoimmune encephalitis often affect women of childbearing age. Pathogenic antibodies of these diseases can potentially alter reproductive functions and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in neurology Ročník 13; s. 1048502
Hlavní autoři: Cortese, Rosa, Mariotto, Sara, Mancinelli, Chiara Rosa, Tortorella, Carla
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media S.A 19.12.2022
Témata:
ISSN:1664-2295, 1664-2295
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Antibody-mediated central nervous system (CNS) disorders including those associated with aquaporin-4 or myelin oligodendrocyte glycoprotein IgG and autoimmune encephalitis often affect women of childbearing age. Pathogenic antibodies of these diseases can potentially alter reproductive functions and influence fetal development. Hormonal changes occurring during pregnancy may modify the course of autoimmune diseases by influencing relapse risk, attack severity, and affect the delivery and postpartum period. Moreover, balancing treatment related safety issues with the risk of potentially disabling relapses during pregnancy and breastfeeding are major challenges. Intentional prenatal, gestational, and post-partum counseling is paramount to address these issues and mitigate these risks. Fortunately, new insights on risk factors for adverse pregnancy outcomes and possible preventive strategies are emerging. This review aims to summarize the interplay between antibody-mediated CNS disorders and pregnancy during the prenatal, gestational, and postpartum periods, highlight current treatment recommendations, and discuss future areas of research.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Rana Khalil Zabad, University of Nebraska Medical Center, United States; Jodie Burton, University of Calgary, Canada
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
Edited by: Antonia Ceccarelli, Centre Hospitalier EpiCURA/Free University of Brussels (UZ Brussel) VUB, Belgium
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2022.1048502